Did You Know?
Innocrin Pharmaceuticals' clinical study INO-VT-464-CL-006 is evaluating the safety, tolerability, pharmacokinetics and activity of seviteronel (VT-464),
a lyase-selective inhibitor of CYP17 and androgen receptor antagonist,
in men with advanced breast cancer.
Just edit this element to add your own HTML.
About 2,000 men are diagnosed
with breast cancer each year.
To the Clarity Male Breast Cancer Study Information Page
To learn more about the study, call 1-800-713-6818
Treatment option for male breast cancer
The Male Breast Cancer study is currently enrolling patients across the U.S. Contact us today to find a participating clinic near you.
A number of factors can increase a man's risk of getting breast cancer including but not limited to: